Szentiványi, Mátyás

Mátyás Szentiványi MD PhD. graduated from Semmelweis University of Medicine and received his MD degree in 1992. He worked six years as a researcher at the same university and two years at the Medical College of Wisconsin in Milwaukee (USA). His field of interest was vascular physiology, renal physiology, and hypertension. He received his PhD degree at the Semmelweis University of Medicine in 2002. The title of his PhD thesis was „Adaptive control mechanisms of the saphenous region”.

Since 2000 he works in pharma business, in the first five years at a big CRO (Quintiles), while in the last twelve years at a multinational pharmaceutical company (Roche). Currently he is the medical director of Roche in Hungary. He has broad experience in clinical research and significant medical affairs experience working in oncology, haematology, and hepatology. Current responsibilities include heading the medical department and overseeing its different units (medical affairs, clinical trials, regulatory, pharmacovigilance). Additional responsibilities include taking part in the company’s leadership team and compliance board. Since 2011 he is a member of the Communication Ethics Committee of the Hungarian Pharma Associations.

Mátyás Szentiványi is first author of 6 articles in international scientific journals and second author of 5 articles. He presented 21 scientific presentations in international scientific meetings.

Main publications:
1. Szentiványi M Jr et al. Am J Physiol. 271: H2238-H2245. 1996
2. Szentiványi M Jr et al. Circ. Res. 81: 988-995. 1997
3. Szentiványi M Jr et al. Hypertension 33: 440-445. 1999
4. Szentiványi M Jr et al. Hypertension 35: 418-423. 2000
5. Szentiványi M Jr et al. Hypertension 35: 740-745. 2000
6. Szentiványi M Jr et al. Am J Physiol 283: R266-R272. 2002

Next Generation Sequencing: The Future of Personalised Healthcare (PHC 2.0)

Innovative drugs significantly contribute to the success of our healthcare including to the fight against cancer. Some drugs act in specific patient populations which require different diagnostic tools. This is called Personalised Healthcare (PHC) where a given proportion of the patients can be chosen who will have better chance to respond to a given drug. Evidence shows that personalised targeted therapies are associated with significantly better outcomes than cytotoxic agents. However, this approach is unable to treat a significant portion of the patients and many patients do not have access to novel diagnostics and medicines. Therefore a new method is necessary to give an even higher chance to cancer survival with a good quality of life. The technology of Next Generation Sequencing (NGS) combined with setting up new databases enables us to find the ways how a single patient can be treated. With NGS more genetic alterations associated to different cancer types can be found than with single gene testing, the current method. This is called PHC 2.0 which provides new treatment options to 70 % of the patients including off-label use of current treatments and targeted enrollment into clinical trials. This latter can improve the recruitment of the trials resulting in faster and more accurate drug development which will save money for the society. In addition PHC 2.0 shows to appr. 10 % of the patients that no current treatments are available for them saving them from the side effects and other complications of any drug currently available on the market. In conclusion, new genomic sequencing technology (NGS) together with advanced bioinformatics and reporting are available to help physicians understand patient tumour profiles and improve personalised patient care.

References: Schwaederle et al. Mol Cancer Ther 2015. Frampton et al. Nat. Biotechnol. 2013.